KR20010022758A - Support for patches and patches provided with the support - Google Patents
Support for patches and patches provided with the support Download PDFInfo
- Publication number
- KR20010022758A KR20010022758A KR1020007001358A KR20007001358A KR20010022758A KR 20010022758 A KR20010022758 A KR 20010022758A KR 1020007001358 A KR1020007001358 A KR 1020007001358A KR 20007001358 A KR20007001358 A KR 20007001358A KR 20010022758 A KR20010022758 A KR 20010022758A
- Authority
- KR
- South Korea
- Prior art keywords
- patch
- support member
- support
- substrate
- adhesive
- Prior art date
Links
- 239000000853 adhesive Substances 0.000 claims abstract description 98
- 230000001070 adhesive effect Effects 0.000 claims abstract description 98
- 239000000758 substrate Substances 0.000 claims abstract description 54
- 239000000463 material Substances 0.000 claims abstract description 52
- 239000000123 paper Substances 0.000 claims abstract description 29
- 239000004744 fabric Substances 0.000 claims abstract description 13
- 239000004745 nonwoven fabric Substances 0.000 claims abstract description 7
- 239000002985 plastic film Substances 0.000 claims abstract description 6
- 229920006255 plastic film Polymers 0.000 claims abstract description 6
- -1 polypropylene Polymers 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 7
- 229920002678 cellulose Polymers 0.000 claims description 7
- 239000001913 cellulose Substances 0.000 claims description 7
- 239000004952 Polyamide Substances 0.000 claims description 6
- 239000004698 Polyethylene Substances 0.000 claims description 6
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 claims description 6
- 229920002647 polyamide Polymers 0.000 claims description 6
- 229920000573 polyethylene Polymers 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 229920000298 Cellophane Polymers 0.000 claims description 5
- 229920000742 Cotton Polymers 0.000 claims description 5
- 239000004743 Polypropylene Substances 0.000 claims description 5
- 239000000835 fiber Substances 0.000 claims description 5
- 239000002655 kraft paper Substances 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 229920000515 polycarbonate Polymers 0.000 claims description 5
- 239000004417 polycarbonate Substances 0.000 claims description 5
- 229920000728 polyester Polymers 0.000 claims description 5
- 229920001155 polypropylene Polymers 0.000 claims description 5
- 229920001577 copolymer Polymers 0.000 claims description 3
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 2
- 229940088679 drug related substance Drugs 0.000 claims description 2
- 230000001681 protective effect Effects 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 206010052428 Wound Diseases 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
- 201000004384 Alopecia Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000000730 antalgic agent Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 208000024963 hair loss Diseases 0.000 description 4
- 230000003676 hair loss Effects 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000002085 irritant Substances 0.000 description 4
- 231100000021 irritant Toxicity 0.000 description 4
- 230000037307 sensitive skin Effects 0.000 description 4
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 3
- 239000000006 Nitroglycerin Substances 0.000 description 3
- 208000004210 Pressure Ulcer Diseases 0.000 description 3
- 239000002390 adhesive tape Substances 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 230000002921 anti-spasmodic effect Effects 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 229960003711 glyceryl trinitrate Drugs 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000003589 local anesthetic agent Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229940124549 vasodilator Drugs 0.000 description 3
- 239000003071 vasodilator agent Substances 0.000 description 3
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 239000003570 air Substances 0.000 description 2
- VIROVYVQCGLCII-UHFFFAOYSA-N amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 239000003793 antidiarrheal agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 229940124575 antispasmodic agent Drugs 0.000 description 2
- 239000003434 antitussive agent Substances 0.000 description 2
- 229940124584 antitussives Drugs 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 238000005452 bending Methods 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229940124630 bronchodilator Drugs 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 229940066493 expectorants Drugs 0.000 description 2
- 239000000417 fungicide Substances 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 229940126904 hypoglycaemic agent Drugs 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 229940124583 pain medication Drugs 0.000 description 2
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920006254 polymer film Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229960001722 verapamil Drugs 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- DTGKSKDOIYIVQL-NQMVMOMDSA-N (+)-Borneol Natural products C1C[C@]2(C)[C@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-NQMVMOMDSA-N 0.000 description 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- UHSXRTHJCJGEKG-UQKRIMTDSA-N (1s)-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-2-ium-6,7-diol;chloride Chemical compound Cl.COC1=C(OC)C(OC)=CC(C[C@H]2C3=CC(O)=C(O)C=C3CCN2)=C1 UHSXRTHJCJGEKG-UQKRIMTDSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- STMOVTSFWYRCOB-DKWTVANSSA-N (2s)-2-amino-3-hydroxypropanoic acid;hydrochloride Chemical compound Cl.OC[C@H](N)C(O)=O STMOVTSFWYRCOB-DKWTVANSSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 description 1
- HEYSRYRYZNGDRS-TYYBGVCCSA-N (e)-but-2-enedioic acid;hydrobromide Chemical compound Br.OC(=O)\C=C\C(O)=O HEYSRYRYZNGDRS-TYYBGVCCSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- GJHKWLSRHNWTAN-UHFFFAOYSA-N 1-ethoxy-4-(4-pentylcyclohexyl)benzene Chemical compound C1CC(CCCCC)CCC1C1=CC=C(OCC)C=C1 GJHKWLSRHNWTAN-UHFFFAOYSA-N 0.000 description 1
- IEEGSJSTKTYDQP-UHFFFAOYSA-N 1-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione Chemical compound O=C1N(CC)C(=O)NC(=O)C1C1=CC=CC=C1 IEEGSJSTKTYDQP-UHFFFAOYSA-N 0.000 description 1
- BGGVJKGMDWLNRC-UHFFFAOYSA-N 1-methoxy-n,n-dimethylethanamine Chemical compound COC(C)N(C)C BGGVJKGMDWLNRC-UHFFFAOYSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- GPNYZBKIGXGYNU-UHFFFAOYSA-N 2-tert-butyl-6-[(3-tert-butyl-5-ethyl-2-hydroxyphenyl)methyl]-4-ethylphenol Chemical compound CC(C)(C)C1=CC(CC)=CC(CC=2C(=C(C=C(CC)C=2)C(C)(C)C)O)=C1O GPNYZBKIGXGYNU-UHFFFAOYSA-N 0.000 description 1
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 description 1
- AKZCUBOMEUSNQI-UHFFFAOYSA-N 6-chloro-3,4-dihydro-2h-1,2,4-benzothiadiazine-7-sulfonamide Chemical compound S1NCNC2=C1C=C(S(=O)(=O)N)C(Cl)=C2 AKZCUBOMEUSNQI-UHFFFAOYSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- KFYRPLNVJVHZGT-UHFFFAOYSA-N Amitriptyline hydrochloride Chemical compound Cl.C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KFYRPLNVJVHZGT-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- VMIYHDSEFNYJSL-UHFFFAOYSA-N Bromazepam Chemical compound C12=CC(Br)=CC=C2NC(=O)CN=C1C1=CC=CC=N1 VMIYHDSEFNYJSL-UHFFFAOYSA-N 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N Butanol Natural products CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- 241000131283 Cantharis Species 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- ZNIFSRGNXRYGHF-UHFFFAOYSA-N Clonidine hydrochloride Chemical compound Cl.ClC1=CC=CC(Cl)=C1NC1=NCCN1 ZNIFSRGNXRYGHF-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- RXKMOPXNWTYEHI-RDRKJGRWSA-N Flunarizine hydrochloride Chemical compound Cl.Cl.C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 RXKMOPXNWTYEHI-RDRKJGRWSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- XQLWNAFCTODIRK-UHFFFAOYSA-N Gallopamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC(OC)=C(OC)C(OC)=C1 XQLWNAFCTODIRK-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 description 1
- WDZVGELJXXEGPV-YIXHJXPBSA-N Guanabenz Chemical compound NC(N)=N\N=C\C1=C(Cl)C=CC=C1Cl WDZVGELJXXEGPV-YIXHJXPBSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- WFWLQNSHRPWKFK-UHFFFAOYSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1C1OCCC1 WFWLQNSHRPWKFK-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- RSLNRVYIRDVHLY-UHFFFAOYSA-N Tulobuterol hydrochloride Chemical compound [Cl-].CC(C)(C)[NH2+]CC(O)C1=CC=CC=C1Cl RSLNRVYIRDVHLY-UHFFFAOYSA-N 0.000 description 1
- DDNCQMVWWZOMLN-IRLDBZIGSA-N Vinpocetine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OCC)N5C2=C1 DDNCQMVWWZOMLN-IRLDBZIGSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- ARHWPKZXBHOEEE-UHFFFAOYSA-N alclofenac Chemical compound OC(=O)CC1=CC=C(OCC=C)C(Cl)=C1 ARHWPKZXBHOEEE-UHFFFAOYSA-N 0.000 description 1
- 229960005142 alclofenac Drugs 0.000 description 1
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 1
- 229960002535 alfacalcidol Drugs 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960000852 alprenolol hydrochloride Drugs 0.000 description 1
- 229960000985 ambroxol hydrochloride Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960005119 amitriptyline hydrochloride Drugs 0.000 description 1
- 229960001301 amobarbital Drugs 0.000 description 1
- PHFDAOXXIZOUIX-UHFFFAOYSA-N anipamil Chemical compound C=1C=CC(OC)=CC=1C(CCCCCCCCCCCC)(C#N)CCCN(C)CCC1=CC=CC(OC)=C1 PHFDAOXXIZOUIX-UHFFFAOYSA-N 0.000 description 1
- 229950011530 anipamil Drugs 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 229940125688 antiparkinson agent Drugs 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000002763 arrhythmic effect Effects 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- YEJAJYAHJQIWNU-UHFFFAOYSA-N azelastine hydrochloride Chemical compound Cl.C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 YEJAJYAHJQIWNU-UHFFFAOYSA-N 0.000 description 1
- 229960004335 azelastine hydrochloride Drugs 0.000 description 1
- 229960005149 bendazac Drugs 0.000 description 1
- BYFMCKSPFYVMOU-UHFFFAOYSA-N bendazac Chemical compound C12=CC=CC=C2C(OCC(=O)O)=NN1CC1=CC=CC=C1 BYFMCKSPFYVMOU-UHFFFAOYSA-N 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229960002729 bromazepam Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 229960000330 bupranolol Drugs 0.000 description 1
- HQIRNZOQPUAHHV-UHFFFAOYSA-N bupranolol Chemical compound CC1=CC=C(Cl)C(OCC(O)CNC(C)(C)C)=C1 HQIRNZOQPUAHHV-UHFFFAOYSA-N 0.000 description 1
- 229960001889 buprenorphine hydrochloride Drugs 0.000 description 1
- UAIXRPCCYXNJMQ-RZIPZOSSSA-N buprenorphine hydrochlorie Chemical compound [Cl-].C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)C[NH+]2CC1CC1 UAIXRPCCYXNJMQ-RZIPZOSSSA-N 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 229940095758 cantharidin Drugs 0.000 description 1
- DHZBEENLJMYSHQ-XCVPVQRUSA-N cantharidin Chemical compound C([C@@H]1O2)C[C@@H]2[C@]2(C)[C@@]1(C)C(=O)OC2=O DHZBEENLJMYSHQ-XCVPVQRUSA-N 0.000 description 1
- 229930008397 cantharidin Natural products 0.000 description 1
- DHZBEENLJMYSHQ-UHFFFAOYSA-N cantharidine Natural products O1C2CCC1C1(C)C2(C)C(=O)OC1=O DHZBEENLJMYSHQ-UHFFFAOYSA-N 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- OPXKTCUYRHXSBK-UHFFFAOYSA-N clenbuterol hydrochloride Chemical compound Cl.CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 OPXKTCUYRHXSBK-UHFFFAOYSA-N 0.000 description 1
- 229960001399 clenbuterol hydrochloride Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 229960002925 clonidine hydrochloride Drugs 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- ZPMVNZLARAEGHB-UHFFFAOYSA-N cyproheptadine hydrochloride (anhydrous) Chemical compound Cl.C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 ZPMVNZLARAEGHB-UHFFFAOYSA-N 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- UQXKXGWGFRWILX-UHFFFAOYSA-N ethylene glycol dinitrate Chemical compound O=N(=O)OCCON(=O)=O UQXKXGWGFRWILX-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- SGZRQMALQBXAIQ-UHFFFAOYSA-N fenoterol hydrobromide Chemical compound Br.C=1C(O)=CC(O)=CC=1C(O)CNC(C)CC1=CC=C(O)C=C1 SGZRQMALQBXAIQ-UHFFFAOYSA-N 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 229960002807 flunarizine hydrochloride Drugs 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960000457 gallopamil Drugs 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002462 glycopyrronium bromide Drugs 0.000 description 1
- 229960003050 guanabenz acetate Drugs 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- CYWFCPPBTWOZSF-UHFFFAOYSA-N ibufenac Chemical compound CC(C)CC1=CC=C(CC(O)=O)C=C1 CYWFCPPBTWOZSF-UHFFFAOYSA-N 0.000 description 1
- 229950009183 ibufenac Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- YQZBAXDVDZTKEQ-UHFFFAOYSA-N loxapine succinate Chemical compound [H+].[H+].[O-]C(=O)CCC([O-])=O.C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 YQZBAXDVDZTKEQ-UHFFFAOYSA-N 0.000 description 1
- 229950004407 mabuterol Drugs 0.000 description 1
- JSJCTEKTBOKRST-UHFFFAOYSA-N mabuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(C(F)(F)F)=C1 JSJCTEKTBOKRST-UHFFFAOYSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960004992 maprotiline hydrochloride Drugs 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229960005042 mequitazine Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- CMUHZRATLMUDJI-UHFFFAOYSA-N methyl 2h-pyridine-1-carboxylate Chemical compound COC(=O)N1CC=CC=C1 CMUHZRATLMUDJI-UHFFFAOYSA-N 0.000 description 1
- LZULAZTXJLWELL-UHFFFAOYSA-N methyl hex-5-ynoate Chemical compound COC(=O)CCCC#C LZULAZTXJLWELL-UHFFFAOYSA-N 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229960005195 morphine hydrochloride Drugs 0.000 description 1
- XELXKCKNPPSFNN-BJWPBXOKSA-N morphine hydrochloride trihydrate Chemical compound O.O.O.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XELXKCKNPPSFNN-BJWPBXOKSA-N 0.000 description 1
- 229960004715 morphine sulfate Drugs 0.000 description 1
- GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- AIKVCUNQWYTVTO-UHFFFAOYSA-N nicardipine hydrochloride Chemical compound Cl.COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 AIKVCUNQWYTVTO-UHFFFAOYSA-N 0.000 description 1
- 229960002289 nicardipine hydrochloride Drugs 0.000 description 1
- 229960002497 nicorandil Drugs 0.000 description 1
- LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229940059574 pentaerithrityl Drugs 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- 229940116257 pepper extract Drugs 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- CHOBRHHOYQKCOU-UHFFFAOYSA-N phenbenzamine Chemical compound C=1C=CC=CC=1N(CCN(C)C)CC1=CC=CC=C1 CHOBRHHOYQKCOU-UHFFFAOYSA-N 0.000 description 1
- 229950003863 phenbenzamine Drugs 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- WFXFYZULCQKPIP-UHFFFAOYSA-N prazosin hydrochloride Chemical compound [H+].[Cl-].N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 WFXFYZULCQKPIP-UHFFFAOYSA-N 0.000 description 1
- 229960002386 prazosin hydrochloride Drugs 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960002789 procaterol hydrochloride Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229960004482 quinidine sulfate Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940071182 stannate Drugs 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 229960005105 terbutaline sulfate Drugs 0.000 description 1
- KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 229960005221 timolol maleate Drugs 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- HWKQNAWCHQMZHK-UHFFFAOYSA-N trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 description 1
- 229960002485 trolnitrate Drugs 0.000 description 1
- 229960004846 tulobuterol hydrochloride Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 239000001243 zingiber officinale rosc. root absolute Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/023—Adhesive bandages or dressings wound covering film layers without a fluid retention layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0246—Adhesive bandages or dressings characterised by the skin-adhering layer
- A61F13/0256—Adhesive bandages or dressings characterised by the skin-adhering layer characterized by the parametric properties of the adhesive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0259—Adhesive bandages or dressings characterised by the release liner covering the skin adhering layer
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Materials For Medical Uses (AREA)
Abstract
본 발명은 패치의 기재의 점착면과 반대측의 면에 부착하여, 기재에 일시적으로 강성을 갖게 하기 위한 패치용 지지구에 있어서, 포, 종이, 부직포, 플라스틱 필름 등으로 이루어진 적절한 강성을 갖는 부재(2)의 한 면에, 패치의 점도보다 낮은 점성을 갖는 점착면(3)과, 점착면(3)과 반대측의 면에 손가락 등을 삽입할 수 있는 통형상 또는 자루 형상 벨트부(4)로 구성되어 있다. 한편, 미리 이 지지구를 부착한 패치도 포함된다.The present invention provides a patch support for attaching to a surface opposite to the adhesive side of a base material of a patch to give the substrate a temporary rigidity, comprising a member having appropriate rigidity made of cloth, paper, nonwoven fabric, plastic film, or the like. On one side of 2), the adhesive face 3 having a viscosity lower than the viscosity of the patch, and a cylindrical or bag-shaped belt portion 4 in which a finger or the like can be inserted into the face opposite to the adhesive face 3. Consists of. On the other hand, the patch which attached this support beforehand is also included.
Description
외용 소염진통제 등의 패치는 기재와, 이 기재의 한 면에 형성된 고체(膏體)로 이루어지고, 고체 등에는 예컨대, 소염진통제용의 경피적용가능한 약효성분을 포함하고 있다. 또한, 통상 사용하기까지의 간고체(間膏體) 등이 형성된 점착면의 더러움이나 건조를 막기 위해, 점착면을 보호용 필름 등으로 피복하고 있다.The patch of an external anti-inflammatory analgesic etc. consists of a base material and the solid formed in one side of this base material, and the solid etc. contain the percutaneous applicable drug substance for anti-inflammatory analgesic, for example. Moreover, in order to prevent the dirt and drying of the adhesion surface in which the liver solid etc. until normal use were formed, the adhesion surface is coat | covered with a protective film or the like.
이러한 패치는 환자 또는 제삼자가 고체 등이 형성된 점착면에서 보호용 필름 등을 벗긴 후에, 점착면측이 환부에 부착하도록 부착시켜 사용한다.Such a patch is used after the patient or a third party peels off the protective film or the like from the adhesive face on which the solid or the like is formed, and then adheres the adhesive face side to the affected part.
이러한 패치에 있어서는, 근년, 환부로의 부착성을 향상시키기 위해 고체 등의 중량을 감함과 동시에, 부착후의 감촉을 좋게 하기 위해 부드럽고 얇은 기재를 사용한 것이 주류로 되어 있다.In such a patch, in recent years, in order to improve the adhesiveness to the affected part, a soft and thin base material is mainly used to reduce the weight of solids and the like and to improve the texture after adhesion.
이러한 패치는 부드러운 기재를 사용하고 있기 때문에, 부착후도 양호한 감촉을 얻을 수 있고, 특히, 환부가 울룩불룩하거나, 만곡부인 경우에도 부착하기 쉽고 충분히 밀착성이 얻어지며, 관절 부위 등에 부착한 경우에도 관절 등을 굽히거나 펴는데 방해하지 않는 등의 이점이 있다.Since such a patch uses a soft base material, a good texture can be obtained even after attachment. Particularly, even when the affected part is bulging or curved, it is easy to attach and sufficient adhesion is obtained. There is an advantage such as not to interfere with bending or straightening the back.
그렇지만, 반면에, 기재가 부드럽고 얇기 때문에 부적당함도 있다.On the other hand, however, there are also inadequacies because the substrate is soft and thin.
즉, 사용단계에서, 상술한 점착면에서 보호용 필름 등을 벗길 때에, 기재가 흐물흐물해지기 때문에, 점착면끼리 달라 붙는 문제가 생기기 쉽다. 또한, 특히, 환자가 혼자서 환부에 부착하는 경우에, 보호용 필름 등을 벗기고 나서, 손이 닿기 어려운 어깨나 등, 허리 등의 환부에 붙일 때에, 패치를 가져가기 어렵고, 더구나 점착면끼리 쉽게 달라 붙는 문제를 피할 수 없다.That is, in the use step, when the protective film or the like is peeled off from the adhesive face described above, the base material becomes mushy, so that the adhesive faces tend to stick together. In addition, especially when the patient attaches to the affected part alone, when the protective film or the like is peeled off and then stuck to the affected part such as the shoulder or back, which is hard to reach, it is difficult to take the patch, and moreover, the adhesive faces easily adhere to each other. The problem is inevitable.
본 발명의 제 1 목적은 부드러운 기재를 갖춘 패치이더라도, 점착면끼리 달라 붙는 것을 방지할 수 있고, 어깨, 등, 허리 등의 환부에도 부착하기 쉽게 하는 패치용 지지구를 제공하는데 있다.A first object of the present invention is to provide a patch support for preventing a sticking surface from sticking even to a patch having a soft base material and making it easy to attach to affected parts such as a shoulder, a back, a waist, and the like.
본 발명의 제 2 목적은 부드러운 기재를 갖춘 패치로서의 상술한 이점을 살리면서, 점착면끼리 달라 붙는 일이 없고, 어깨, 등, 허리 등의 환부에도 환자가 스스로 부착하기 쉬운 패치를 제공하는데 있다.A second object of the present invention is to provide a patch that is easy to attach to a patient, such as a shoulder, a back, a waist, and the like, without sticking the adhesive surfaces to each other while utilizing the above-mentioned advantages as a patch having a soft base material.
본 발명은 외용 소염진통제 등의 패치를 환부에 부착할 때에 사용되는 지지구 및 그 지지구를 구비한 패치에 관한 것이다.The present invention relates to a support used for attaching a patch such as an external anti-inflammatory analgesic agent to the affected part, and a patch provided with the support.
도 1은 본 발명의 제 1 실시예에 관한 패치용 지지구를, 그 박리지를 일부 박리한 상태의 점착면측에서 본 사시도,1 is a perspective view of the patch support according to the first embodiment of the present invention as seen from the side of the adhesive surface in a state where a part of the release paper is peeled off;
도 2는 도 1에 도시된 패치용 지지구를 점착면과 반대측의 면에서 본 사시도,Figure 2 is a perspective view of the patch support shown in Figure 1 seen from the side opposite to the adhesive surface,
도 3은 도 1에 도시된 패치용 지지구를 패치와 접착시킨 상태의 사시도,Figure 3 is a perspective view of the patch supporter shown in Figure 1 bonded to the patch,
도 4는 도 3에 도시한 바와 같이 패치용 지지구를 접착시킨 패치를 환부에 부착하는 상태를 나타내는 사시도, 및4 is a perspective view showing a state in which a patch to which a support for a patch is attached as shown in FIG. 3 is attached to an affected part, and
도 5는 본 발명의 제 2 실시예에 관한 패치의 사시도.5 is a perspective view of a patch according to a second embodiment of the present invention.
＜도면의 주요부분에 대한 부호의 설명＞<Description of the code | symbol about the principal part of drawing>
1: 패치용 지지구 2;12: 지지부재1: support for patch 2; 12: support member
3: 점착면 4;13: 벨트부3: adhesive side 4:13: belt part
5: 박리지 6;8: 패치5: release paper 6; 8: patch
9: 기재9: description
본 발명에서는 상기 제 1 목적을 달성하기 위해, 패치를 부착할 때에, 지지구에 의해 패치의 기재에 일시적으로 강성을 갖게 하여, 점착면끼리 달라 붙는 것을 방지하도록 하고 있다.In this invention, in order to achieve the said 1st objective, when attaching a patch, the base material of a patch is temporarily made rigid by a support tool, and it is trying to prevent sticking surfaces.
즉, 본 발명의 한 형태에 의하면, 유연성을 갖는 기재를 갖춘 패치를 환부에 부착할 때에, 이 패치의 상기 기재를 지지하기 위해 일시적으로 사용하는 지지구로서, 상기 기재의 비부착측에 접착되는 지지부재와, 이 지지부재에 형성된 벨트부를 구비하고, 상기 지지부재는 상기 기재와 접착된 때에 기재의 평면성을 유지할 수 있는 크기와 강성을 가지며, 패치의 점착면의 점착력보다 낮은 부착력을 갖는 부착수단에 의해 상기 기재의 비부착측에 접착되는 것을 특징으로 하는 패치용 지지구를 얻을 수 있다.That is, according to one aspect of the present invention, when attaching a patch having a flexible substrate to the affected part, the support is temporarily used to support the substrate of the patch, and is adhered to the non-attached side of the substrate. And a support member and a belt portion formed on the support member, wherein the support member has a size and rigidity capable of maintaining the planarity of the substrate when bonded to the substrate, and having attachment force lower than that of the adhesive face of the patch. It is possible to obtain a support for a patch, which is adhered to the non-attached side of the base material.
또한, 상기 지지부재는 상기 기재와 대략 동일한 크기의 시트상으로 형성되고, 상기 부착수단은 시트상 지지부재의 한 면에 형성되며, 상기 패치의 점착면의 점착력보다 낮은 점성을 갖는 다른 점착면으로 구성하는 것이 가능하다.In addition, the support member is formed in a sheet shape of approximately the same size as the base material, the attachment means is formed on one side of the sheet-like support member, the other adhesive surface having a viscosity lower than the adhesive force of the adhesive surface of the patch It is possible to configure.
상기 벨트부는 상기 지지부재의 다른 면에 형성되고, 손가락을 삽입할 수 있는 통형상부 또는 자루 형상부에 의해 구성할 수 있다.The belt portion is formed on the other side of the support member, and may be constituted by a tubular portion or a bag portion into which a finger can be inserted.
한편, 상기 다른 점착면은 박리지로 피복하여 보호하는 것이 적합하다.On the other hand, it is suitable to coat and protect the said other adhesive surface with release paper.
또한 상기 지지부재는 면포, 재생 셀룰로스포, 화학섬유포, 부직포 등의 포류, 일본 종이, 크라프트지 등의 종이류, 경질 염화비닐, 폴리프로필렌, 폴리에틸렌, 폴리에스테르, 폴리아미드, 폴리카보네이트, 및 이들 공중합체, 셀로판 등의 플라스틱 필름, 금속 박편, 또는 이들 적층체로 구성할 수 있다.The support member may also include cotton cloth, recycled cellulose spores, chemical fiber cloths, nonwoven fabrics, papers such as Japanese paper, kraft paper, hard vinyl chloride, polypropylene, polyethylene, polyester, polyamides, polycarbonates, and copolymers thereof. It can be comprised from plastic films, such as cellophane, metal flakes, or these laminated bodies.
상기 설명에 덧붙여, 본 발명에서는 상기 제 2 목적을 달성하기 위해, 미리 상기 벨트부를 포함하는 지지부재를 기재의 점착면과 반대측의 면에 서로 접착시켜서 된 패치를 구성하고, 패치를 부착한 후는 상기 벨트부를 포함하는 지지부재를 상기기재로부터 벗겨, 상기 기재와 약효성분 만을 사용하도록 하고 있다.In addition to the above description, in the present invention, in order to achieve the second object, the support member including the belt portion is bonded to each other on the surface opposite to the adhesive surface of the substrate, and after the patch is attached, The support member including the belt portion is peeled from the base material so that only the base material and the active ingredient are used.
즉, 본 발명의 다른 형태에 의하면, 유연성을 갖는 기재와, 이 기재에 포함 된 약효성분을 가지며, 상기 기재에 형성된 점착면에 의해 환부에 부착되는 패치에 있어서, 상기 기재의 비부착측에 접착된 지지부재와, 이 지지부재에 형성된 벨트부를 가지며, 상기 지지부재는 상기 기재의 평면성을 유지할 수 있는 크기와 강성을 갖고, 상기 기재의 점착면의 점착력보다 낮은 부착력을 갖는 부착수단에 의해 이 기재의 비부착측에 접착되며, 상기 패치가 환부에 부착된 후는 상기 벨트부를 포함하는 지지부재가 상기 기재에서 벗겨지고, 상기 기재와 약효성분이 사용되는 것을 특징으로 하는 패치를 얻을 수 있다.That is, according to another aspect of the present invention, in a patch having a flexible base material and a drug active ingredient contained in the base material and adhered to the affected part by an adhesive surface formed on the base material, it is adhered to the non-adhesive side of the base material. The support member and a belt portion formed on the support member, the support member having a size and rigidity capable of maintaining the planarity of the substrate and having an adhesion force lower than that of the adhesive surface of the substrate. After the adhesive is adhered to the non-adhesive side, the patch is attached to the affected part, and the support member including the belt portion is peeled off from the substrate, and the patch may be obtained, wherein the substrate and the active ingredient are used.
또한, 상기 지지부재는 상기 기재와 대략 동일한 크기의 시트상으로 형성되고, 상기 부착수단은 시트상 지지부재의 한 면에 형성되며, 상기 기재의 점착면의 점착력보다 낮은 점성을 갖는 다른 점착면으로 구성될 수 있다.In addition, the support member is formed in a sheet shape of approximately the same size as the substrate, the attachment means is formed on one side of the sheet-like support member, the other adhesive surface having a lower viscosity than the adhesive force of the adhesive surface of the substrate Can be configured.
더구나, 상기 벨트부는 상기 지지부재의 다른 면에 형성되고, 손가락을 삽입할 수 있는 통형상부 또는 자루 형상부로 구성할 수 있다.In addition, the belt portion is formed on the other surface of the support member, it can be configured as a cylindrical portion or a bag-shaped portion that can insert a finger.
한편, 상기 지지부재는 면포, 재생 셀룰로스포, 화학섬유포, 부직포 등의 포류, 일본 종이, 크라프트지 등의 종이류, 경질 염화비닐, 폴리프로필렌, 폴리에틸렌, 폴리에스테르, 폴리아미드, 폴리카보네이트, 및 이들 공중합체, 셀로판 등의 플라스틱 필름, 금속 박편, 또는 이들 적층체로 구성할 수 있다.On the other hand, the support member includes cotton cloth, recycled cellulose spores, chemical fiber cloths, nonwoven fabrics, papers such as Japanese paper, kraft paper, hard vinyl chloride, polypropylene, polyethylene, polyester, polyamides, polycarbonates, and air It can be comprised from plastic films, such as coalescing and cellophane, metal flakes, or these laminated bodies.
본 발명을 보다 상세히 기술하기 위해, 첨부도면에 의거하여 이것을 설명한다.BRIEF DESCRIPTION OF DRAWINGS To describe the present invention in more detail, this is explained based on the accompanying drawings.
우선, 도 1 내지 도 4를 참조하여, 본 발명의 제 1 실시예에 관한 패치용 지지구에 관해 설명한다. 한편, 본 실시예의 패치용 지지구(1)는 상술한 종래예와 같은 부드럽고 얇은 기재를 사용한 패치와 함께 사용된다.First, with reference to Figs. 1 to 4, a support for a patch according to the first embodiment of the present invention will be described. On the other hand, the patch support 1 of this embodiment is used together with the patch using the soft and thin base material similar to the conventional example mentioned above.
도 1은 지지구로부터 박리지를 일부 박리한 상태를 지지구의 점착면측에서 본 사시도이고, 도 2는 동일하게 지지구를 점착면과 반대측의 면에서 본 사시도이다. 도 3은 지지구를 패치에 접착시킨 상태의 사시도이고, 도 4는 지지구를 접착시킨 패치를 환부에 부착하는 상태의 사시도이다.Fig. 1 is a perspective view of a state where a part of the release paper is peeled off from the support, as seen from the side of the adhesive, and Fig. 2 is a perspective view of the support, similarly seen from the side of the adhesive. 3 is a perspective view of a state in which a support is adhered to a patch, and FIG. 4 is a perspective view of a state in which a patch to which a support is adhered is attached to an affected part.
도 1 내지 도 4에 도시하는 바와 같이, 본 실시예에 관한 패치용 지지구(1)는 그 한 면에 점착면(3)을 갖는 지지부재(2)와, 지지부재(2)의 점착면(3)과 반대측의 면에 형성된 벨트부(4)와, 지지부재(2)의 점착면(3)에 부착된 박리지(5,5)를 갖고 있다.As shown in Figs. 1 to 4, the patch supporter 1 according to the present embodiment has a support member 2 having an adhesive face 3 on one side thereof, and an adhesive face of the support member 2. It has the belt part 4 formed in the surface on the opposite side to (3), and the release papers 5 and 5 attached to the adhesive surface 3 of the support member 2. As shown in FIG.
지지부재(2)는 면포, 재생 셀룰로스포, 화학섬유포, 부직포 등의 포류, 일본 종이, 크라프트지 등의 종이류, 경질 염화비닐, 폴리프로필렌, 폴리에틸렌, 폴리에스테르, 폴리아미드, 폴리카보네이트, 및 이들 공중합체 또는 셀로판 등의 플라스틱 필름 등으로 이루어지고, 적당한 강성을 갖고 있다. 한편, 이러한 강성을 부여하기 위해, 종이류, 포류, 필름류 등 이들 각종 재료의 적층체에 의해 지지부재(2)를 형성하더라도 좋다. 더구나, 지지부재(2)를 금속 박편으로 형성하여 강성을 얻는 것도 고려된다. 본 발명에서는 이 지지부재의 재료나 크기, 형상을 특히 한정하는 것은 아니다. 즉, 지지부재는 어떠한 형상이어도 좋지만, 중요하게는 기재와 접착된 때에 이 기재의 평면성을 유지할 수 있는 정도의 크기와 강성을 갖고 있으면 좋다. 본 실시예와 같이, 기재와 대략 동일한 형상 및 크기를 갖고 있으면, 기재를 충분히 지지하고 쉽고, 제조도 용이하고 사용 편의성도 양호하기 때문에 적절하다. 한편, 지지부재의 강성은 예컨대, 패치가 어깨, 허리 등의 만곡부위에 부착될 때에, 이 만곡부위의 형상에 대응하여 기재가 만곡하는 것을 방해하는 것은 아니다. 즉, 지지부재의 강성은 기재의 점착면끼리 달라 붙지 않도록 기재가 흐물흐물하게 되는 것을 방지할 수 있는 정도로 기재의 평면성을 유지할 수 있으면 족하다.The support member 2 is made of cotton cloth, recycled cellulose spores, chemical fiber cloths, nonwoven fabrics, papers such as Japanese paper, kraft paper, hard vinyl chloride, polypropylene, polyethylene, polyester, polyamide, polycarbonate, and air It consists of plastic films, such as coalescence or cellophane, and has moderate rigidity. On the other hand, in order to impart such rigidity, the supporting member 2 may be formed of a laminate of these various materials such as papers, foams, and films. Furthermore, it is also contemplated that the support member 2 is formed of metal flakes to obtain rigidity. In the present invention, the material, size, and shape of the support member are not particularly limited. That is, the support member may be in any shape, but importantly, it is sufficient if the support member has a size and rigidity that can maintain the planarity of the substrate when bonded to the substrate. As in the present embodiment, if the substrate has substantially the same shape and size as the substrate, the substrate is sufficiently supported, easy to manufacture, easy to use, and easy to use. On the other hand, the rigidity of the support member does not prevent the substrate from bending in response to the shape of the curved portion, for example, when the patch is attached to the curved portion such as the shoulder or waist. That is, the rigidity of the support member is sufficient as long as it can maintain the planarity of the substrate to such an extent that the substrate can be prevented from adhering so that the adhesive surfaces of the substrate do not stick together.
점착면(3)은 패치의 점착면의 점도보다 낮은 점성을 갖고 있다. 한편, 지지부재(2)는 패치를 환부에 부착한 후에, 패치(기재)의 점착면을 환부에서 벗기지 않고, 기재와 분리되어야 한다. 본 발명에서는 지지부재를 기재와 서로 부착시키는 방법을 한정하는 것은 아니고, 중요하게는, 패치(기재)의 점착면의 점착력보다 낮은 부착력을 갖는 부착수단에 의해 기재의 비부착측에 접착되어 있으면 좋다. 따라서, 예컨대 점착면(3)을 형성하지 않고서, 사용시에 양면 테이프를 사용하여 고정하는 것 등에 의해, 지지부재(2)를 기재와 접착시키더라도 좋다. 그렇지만, 본 실시예에서는 지지부재(2)에 미리 패치(기재)의 점착면의 점도보다 낮은 점성을 갖는 점착제에 의해 점착면(3)을 형성한 후에, 박리지(5)로 피복하여, 사용시에 박리지(5)를 벗겨 점착면(3)과 기재(9)를 접착시키도록 하고 있다. 이와 같이 하면, 패치의 제조시에 점도가 다른 2개의 점착면을 일환으로 제조할 수 있고, 또한 지지부재에 의한 기재의 지지도 안정하기 때문에 적절하다.The adhesive face 3 has a viscosity lower than the viscosity of the adhesive face of a patch. On the other hand, after attaching the patch to the affected part, the supporting member 2 should be separated from the substrate without peeling the adhesive surface of the patch (substrate) from the affected part. In the present invention, the supporting member is not limited to the method of adhering to the base material, and it is important that it is attached to the non-adhesive side of the base material by an attachment means having an adhesion force lower than that of the adhesive face of the patch (base material). . Therefore, the support member 2 may be adhered to the substrate by, for example, fixing using a double-sided tape at the time of use without forming the adhesive face 3. However, in this embodiment, after forming the adhesive surface 3 by the adhesive which has a viscosity lower than the viscosity of the adhesive surface of a patch (substrate) in the support member 2 previously, it coat | covers with the release paper 5, and is used at the time of use. The release paper 5 is peeled off so that the adhesive face 3 and the base material 9 are bonded together. In this case, two adhesive surfaces having different viscosities can be produced as part of the patch production, and the support of the substrate by the support member is also stable.
벨트부(4)는 지지부재(2)를 사용자의 손가락 등에 장착하기 위한 것이고, 본 발명에서는 이 벨트부의 재료나 크기, 형상도 특히 한정하는 것은 아니다. 즉, 벨트부는 어떠한 크기, 형상이어도 좋고, 특히 지지부재와 별체로 형성하지 않고, 예컨대 손가락 등을 삽입할 수 있도록 적당하게 깊숙이 절단하여 사용할 수도 있다. 한편, 본 실시형태에서는 지지부재(2)의 점착면(3)과 반대측의 면에 지지부재(2)와 대략 동일한 형상과 크기를 갖는 띠형 시트를 부가하여, 이 띠형 시트의 양단 주변부를 접착함으로써 벨트부(4)를 통형상으로 구성하였다. 이에 의해, 지지부재, 나아가서는 기재의 평면성을 대략 유지한 채로, 지지부재(2)와 통형상의 벨트부(4) 사이에 손가락 등을 삽입하여 패치를 용이하게 안정하게 부착할 수 있다. 한편, 이 띠형 시트의 소재로는 포, 종이, 부직포, 폴리머 필름 등을 사용할 수 있지만, 본 실시형태에서는 투명한 폴리머 필름을 사용하였다.The belt part 4 is for attaching the support member 2 to a user's finger or the like, and the material, size and shape of the belt part are not particularly limited in the present invention. That is, the belt portion may be of any size and shape, and may be cut and used deeply, for example, to insert a finger or the like without being formed separately from the support member. On the other hand, in this embodiment, by attaching the strip | belt-shaped sheet which has a shape and size substantially the same as the support member 2 to the surface on the opposite side to the adhesive surface 3 of the support member 2, it adhere | attaches the peripheral part of both ends of this strip | belt-shaped sheet. The belt part 4 was comprised in cylindrical shape. Thereby, a finger etc. can be inserted between the support member 2 and the cylindrical belt part 4, and can attach a patch easily and stably, maintaining the planarity of a support member and also a base material substantially. In addition, although a cloth, paper, a nonwoven fabric, a polymer film, etc. can be used as a raw material of this strip | belt-shaped sheet, in this embodiment, the transparent polymer film was used.
박리지(5)는 사용하기까지의 사이, 지지부재(2)의 점착면(3)을 피복하여, 점착면(3)의 더러움이나 건조를 막는 것이다. 한편, 6은 부드럽고 얇은 기재를 사용한 패치, 7은 패치(6)의 점착면을 피복하는 보호용 필름을 나타낸다.The release paper 5 covers the adhesive face 3 of the support member 2 until it is used, and prevents the dirt and drying of the adhesive face 3. In addition, 6 shows the patch using a soft thin base material, 7 shows the protective film which coat | covers the adhesive face of the patch 6. As shown in FIG.
본 실시예의 패치용 지지구(1)에 있어서는, 점착면(3)의 점도는 패치(6)의 점착면의 점도보다 작게 해야 하지만, 이 점도값은 특히 한정되지 않고, 이 기술분야에서 일반적으로 사용되고 있는 재료 중에서 적당히 선택하면 좋다.In the patch support 1 of this embodiment, although the viscosity of the adhesive face 3 should be smaller than the viscosity of the adhesive face of the patch 6, this viscosity value is not specifically limited, Generally in this technical field What is necessary is just to select suitably from the material used.
한편, 점착면을 형성하기 위한 점착제로는 아크릴계, 초산비닐계, 폴리피닐알콜계, 염화비닐계, 폴리아미드계, 폴리에틸렌계, 셀룰로스계 접착제, 젤라틴 등을 사용할 수 있다.On the other hand, as the pressure-sensitive adhesive for forming the adhesive surface, acrylic, vinyl acetate, polypinyl alcohol, vinyl chloride, polyamide, polyethylene, cellulose adhesive, gelatin and the like can be used.
본 실시예의 패치용 지지구(1)의 사용방법에 관해 설명한다.The use method of the patch support 1 of this embodiment is demonstrated.
패치용 지지구(1)를 사용하는 데에는 우선, 도 1 및 도 2에 도시한 바와 같이, 패치용 지지구(1)에서 박리지(5,5)를 벗겨 점착면(3)을 노출시킨다. 한편, 박리지(5.5)는 패치용 지지구(1)에서 완전히 벗겨져, 점착면(3)의 전면을 노출시키는 것이 바람직하다. 후술하는 바와 같이, 패치용 지지구(1)를 재차 사용하지 않는 한, 박리지(5,5)는 벗긴 후 버려도 상관없다.To use the patch support 1, first, as shown in Figs. 1 and 2, the release papers 5 and 5 are peeled off from the patch support 1 to expose the adhesive surface 3. On the other hand, it is preferable that the release paper 5.5 is completely peeled off from the patch support 1 to expose the entire surface of the adhesive face 3. As will be described later, the release papers 5, 5 may be discarded after being peeled off, unless the patch support 1 is used again.
이어서, 패치용 지지구(1)의 점착면(3)을 패치(6)의 점착면과 반대측의 면에 접착시킨다. 이에 따라, 도 3에 도시한 바와 같이, 패치용 지지구(1)와 일체가 된 패치(6)를 얻을 수 있다.Subsequently, the adhesive face 3 of the support for patch 1 is bonded to the side opposite to the adhesive face of the patch 6. Thereby, as shown in FIG. 3, the patch 6 integrated with the patch support 1 can be obtained.
계속해서, 도 4에 도시한 바와 같이, 지지부재(2)와 벨트부(4) 사이에, 예컨대 손가락을 넣어, 이 상태, 즉, 패치용 지지구(1)에 의해 패치(6)를 사용자의 손가락 등으로 지지한 상태에서, 도 3에 도시한 패치(6)의 보호용 필름(7)을 벗겨 패치(6)의 점착면을 노출시킨 후, 원하는 환부에 패치(6)를 부착한다.Subsequently, as shown in FIG. 4, a finger is inserted between the support member 2 and the belt portion 4, for example, so that the patch 6 can be used by the patch support 1 in this state. After peeling off the protective film 7 of the patch 6 shown in FIG. 3 in the state supported by the finger etc., the adhesive surface of the patch 6 is exposed, and the patch 6 is affixed on the desired affected part.
최후에, 환부에 부착된 패치(6)로부터 패치용 지지구(1)를 천천히 벗긴다. 한편, 패치(6)로부터 벗긴 패치용 지지구(1)는 점착면(3)에 다시 박리지(5,5)를 붙이는 등을 행하여 보존하고, 다른 패치(6)를 부착할 때에, 다시 사용할 수도 있지만, 약제를 대상으로 하기 때문에, 위생상 1 회용으로 하는 것이 바람직하다.Finally, the patch support 1 is slowly peeled off from the patch 6 attached to the affected part. On the other hand, the patch support 1 peeled off from the patch 6 is preserved by attaching the release papers 5 and 5 to the adhesive face 3 again, and is used again when attaching another patch 6. Although it is possible to use it as a medicine, it is preferable to use it for disposable use for hygiene.
또한, 본 실시예에서는 패치(6)의 크기와 대략 같은 크기로 형성한 패치용 지지구(1)를 그대로 사용하였지만, 예컨대 환부에 따라 패치(6)를 작게 절단하여 사용하는 경우 등에는, 이것에 따라 패치용 지지구(1)도 절단하여 사용하여도 좋다.In addition, in this embodiment, the patch support 1 formed in the same size as the patch 6 was used as it is, but this is the case, for example, when the patch 6 is cut small and used according to the affected part. According to this, the patch support 1 may also be cut and used.
여기서, 본 실시예에 관한 패치용 지지구의 제조방법에 관해, 그 일례를 설명한다.Here, an example of the manufacturing method of the support for a patch which concerns on a present Example is demonstrated.
패치용 지지구(1)를 제조하는 데에는, 우선, 지지부재에 패치(6)의 점착면의 점도보다 낮은 점도의 점착제를 도포함과 동시에, 박리지를 형성하기 위한 필름을 접착시킨다.In manufacturing the patch support 1, first, an adhesive having a viscosity lower than the viscosity of the adhesive face of the patch 6 is applied to the support member, and a film for forming a release paper is adhered.
다음에, 필름을 접착시킨 지지부재를 건조로에 통과시킨다.Next, the supporting member to which the film is bonded is passed through a drying furnace.
또한, 이렇게 해서 완성된 중간제품을 숙성후, 벨트부를 형성하기 위한 필름을 얹고, 그 양단을 히트 시일한다.Furthermore, after aging the finished intermediate product in this way, a film for forming the belt portion is placed and heat-sealed at both ends thereof.
그리고, 벨트부의 완성후, 박리지를 한가운데로부터 2 개로 나누기 위한 슬릿이나 벨트로의 컷을 필요에 따라 가하면 좋다.Then, after completion of the belt portion, a slit or a cut to the belt for dividing the release paper into two pieces may be added as necessary.
다음에, 도 5를 참조하여, 본 발명의 제 2 실시예에 관한 패치에 대하여 설명한다.Next, with reference to FIG. 5, the patch concerning the 2nd Example of this invention is demonstrated.
도 5에 도시된 바와 같이, 본 실시예에 관한 패치(8)는 미리 기재(9)의 점착면(도시하지 않음)과 반대측의 면에 상술한 제 1 실시예의 지지구에 놓인 것과 대략 같은 구성의 지지부재 및 벨트부를 구비하여 이루어진 것이다. 더구나, 본 실시예의 패치(8)는 상술한 제 1 실시예의 지지구의 박리지(5,5)에 해당하는 것은 갖고 있지 않다.As shown in Fig. 5, the patch 8 according to the present embodiment has a configuration substantially the same as that placed in the support of the first embodiment described above on the side opposite to the adhesive surface (not shown) of the substrate 9 in advance. The support member and the belt portion is made. In addition, the patch 8 of this embodiment does not have the thing corresponding to the release papers 5 and 5 of the support tool of 1st Example mentioned above.
즉, 본 실시예의 패치(8)는 상술한 종래예 및 제 1 실시예에 관한 것과 마찬가지로, 부드럽고 얇게 형성된 기재(9)와, 기재(9)에 도포된 고체(도시하지 않음)를 가지며, 고체에는 소염진통 등의 약효성분을 포함한다. 또한, 사용하기까지의 간고체가 도포된 점착면의 더러움이나 건조를 막기 위해, 점착면을 피복하는 보호용 필름(10)을 구비하고 있다. 본 실시예의 패치(8)는 기재(9)의 점착면과 반대측의 면에 장착된 지지부재(12)와, 지지부재(12)의 접착면과 반대측의 면에 형성된 벨트부(13)를 갖고 있다.That is, the patch 8 of this embodiment has a soft and thin substrate 9 and a solid (not shown) applied to the substrate 9, similarly to the above-described conventional example and the first embodiment. Includes active ingredients such as anti-inflammatory pain. Moreover, the protective film 10 which coat | covers an adhesive surface is provided in order to prevent the dirt and drying of the adhesive surface to which the liver solid before use was apply | coated. The patch 8 of this embodiment has a support member 12 mounted on a surface opposite to the adhesive surface of the substrate 9 and a belt portion 13 formed on the surface opposite to the adhesive surface of the support member 12. have.
지지부재(12)는 상술한 제 1 실시예의 지지부재(2)와 같은 소재로 이루어지고, 적절한 강성을 갖고 있다. 또한, 지지부재(12)는 기재(9)와 대략 동일한 크기로 형성되고, 기재(9)의 점착면과 반대측의 면에 장착되어 있다. 한편, 지지부재(12)는 패치(8)를 환부에 부착시킨 후에, 기재(9)의 점착면을 환부로부터 벗기지 않고, 기재(9)와 분리되어야 한다. 본 발명에서는 지지부재를 기재와 서로 접착시키는 방법을 한정하는 것은 아니고, 중요하게는, 패치(기재)의 점착면의 점착력보다 낮은 부착력을 갖는 부착수단에 의해 기재의 비부착측에 접착되어 있으면 좋다. 따라서, 예컨대 점착제를 쓰지 않고, 단지 복수개소를 클립 등으로 고정함으로써, 지지부재를 기재와 접착시키더라도 좋다. 그렇지만, 본 실시예의 패치(8)에서는 지지부재(12)를 기재(9)의 상술한 점착면, 즉 패치의 점착면의 점도보다 낮은 점성을 갖는 점착제로 기재(9)와 접착시키고 있다. 이와 같이하면, 패치의 제조시에 점도가 다른 2개의 점착면을 일환으로 제조할 수 있고, 또한, 지지부재에 의한 기재의 지지도 안정하기 때문에 바람직하다.The support member 12 is made of the same material as the support member 2 of the first embodiment described above, and has appropriate rigidity. In addition, the support member 12 is formed in substantially the same size as the base material 9, and is attached to the surface on the opposite side to the adhesive surface of the base material 9. On the other hand, the support member 12 should be separated from the substrate 9 without attaching the patch 8 to the affected part, without peeling the adhesive surface of the substrate 9 from the affected part. In the present invention, the support member is not limited to the method of adhering the substrate to each other. Importantly, the support member may be adhered to the non-adhesive side of the substrate by an attachment means having an adhesion force lower than that of the adhesive face of the patch (substrate). . Therefore, the support member may be adhered to the substrate by simply fixing a plurality of places with a clip or the like without using an adhesive, for example. However, in the patch 8 of this embodiment, the supporting member 12 is adhere | attached with the base material 9 with the adhesive which has a viscosity lower than the viscosity of the above-mentioned adhesive surface of the base material 9, ie, the adhesive surface of a patch. In this way, since two adhesive surfaces with different viscosities can be manufactured as a part at the time of manufacture of a patch, since support of a base material by a support member is also stable, it is preferable.
벨트부(13)는 제 1 실시예의 벨트부(4)와 같은 기능을 나타내는 것으로, 본 실시예에서는 지지부재(12)의 기재(9)와 접착시킨 면과 반대측의 면에 지지부재(12)와 대략 동일한 형상 및 크기를 갖는 띠형 시트을 부가하여, 이 띠형 시트의 세 방면의 주변부를 접착함으로써, 자루 형상으로 구성되어 있다.The belt portion 13 exhibits the same function as the belt portion 4 of the first embodiment, and in this embodiment, the support member 12 is disposed on the surface opposite to the surface bonded to the substrate 9 of the support member 12. It is comprised in a bag shape by adding the strip | belt-shaped sheet which has a shape and size substantially the same as that, and adhering the three peripheral parts of this strip | belt-shaped sheet | seat.
그런데, 본 실시예의 패치(8)는 기재(9)의 점착면에서 보호용 필름(10)을 벗긴 후, 자루 형상 벨트부(13)에 그 개구측에서 손가락 등을 삽입하여, 그대로 원하는 환부에 패치(8)를 위치결정한 후에 부착하면 좋다. 한편, 부착한 후에 지지부재(12)를 기재(9)로부터 천천히 벗겨서 분리하는 것은 상술한 제 1 실시예에 관한 것과 마찬가지다.By the way, the patch 8 of this embodiment peels off the protective film 10 from the adhesive surface of the base material 9, and then inserts a finger or the like into the bag-shaped belt part 13 at the opening side thereof, and then patches the desired affected portion as it is. It is good to attach after positioning (8). On the other hand, peeling off and detaching the support member 12 from the base material 9 after sticking is the same as that of the above-mentioned 1st Embodiment.
이상, 본 발명을 특정한 실시예에 관해 기술하였지만, 본 발명을 다른 여러가지 실시형태에 관해 적용하는 것은 당업자에 있어서 용이하다.As mentioned above, although this invention was described about the specific Example, it is easy for a person skilled in the art to apply this invention to various other embodiment.
예컨대, 상술한 제 1 및 제 2 실시예에서는 외용 소염진통제로서의 패치를 환부에 부착할 때에 사용되는 지지구 및 그 지지구를 포함한 패치에 관해 기술한다.For example, the first and second embodiments described above describe a support used for attaching a patch as an external anti-inflammatory analgesic to the affected part and a patch including the support.
그렇지만, 본 발명은 소염진통제 이외에도, 해열소염진통제, 스테로이드계 항염증제, 혈관확장제, 고혈압ㆍ부정맥용제, 혈압강하제, 진해ㆍ거담제, 항종양제, 국소마취제, 호르몬제, 천식ㆍ비성 알레르기 치료제, 항히스타민제, 항응혈제, 진경제, 뇌순환ㆍ대사개선제, 항울ㆍ항불안제, 비타민 D 제제, 혈당강하제, 항궤양제, 수면제, 항생물질, 아드레날린 작동성 기관지확장제, 마약진통제, 이뇨제, 진정제, 항진균제, 살균제, 칼슘길항제, 항퍼킨슨제, 항콜린제, 어깨 결림 치료약, 근육통 치료약, 요통 치료약, 지사약(止寫藥), 욕창용 약제나 피부 궤양 치료제, 냉감성 피부자극성 약물, 온감성 피부자극성 약물, 유해 자외선 흡수제 등, 경피흡수가능한 의약의 약효성분을 포함하는 다른 많은 패치에 관해서도 적용할 수 있다.However, the present invention, in addition to anti-inflammatory analgesics, antipyretic anti-inflammatory drugs, steroidal anti-inflammatory drugs, vasodilators, hypertension and arrhythmia solutions, blood pressure lowering agents, antitussives and expectorants, anti-tumor agents, local anesthetics, hormones, asthma and antiallergic drugs, antihistamines , Anticoagulants, antispasmodics, brain circulation and metabolic improvers, antidepressants, antianxiety agents, vitamin D preparations, hypoglycemic agents, antiulcers, sleeping pills, antibiotics, adrenaline-activated bronchodilators, narcotic analgesics, diuretics, sedatives, antifungals, fungicides, Calcium antagonists, antiperkinsons, anticholiners, stiff shoulders, muscle pain medications, low back pain medications, anti-diarrheal drugs, bed sores or skin ulcers, cold sensitive skin irritants, sensitive skin irritants, harmful ultraviolet rays The present invention can also be applied to many other patches containing medicaments of transdermally absorbable drugs such as absorbents.
특히, 약이 위장을 통과하지 않기 때문에, 비스테로이드성 소염진통제의 부작용인 위장장해의 우려가 없어진다. 또한, 당뇨병약인 인슐린은 현재 주사제밖에 없지만, 패치형을 개발함으로써 환자는 주사시의 아픔으로부터 해방될 뿐만 아니라, 조작 간편성이나 편리성의 은혜도 입을 수 있다.In particular, since the drug does not pass through the stomach, there is no fear of gastrointestinal disorder, which is a side effect of the NSAIDs. In addition, insulin, which is a diabetic drug, is currently the only injection, but by developing a patch type, the patient can not only be freed from the pain at the time of injection, but also benefit from simplicity of operation and convenience.
또한, 용도에 관계없이, 부착 시험(patch test), 환부 지혈, 소독, 보호 등의 목적으로 피부상에 직접 부착하는 의료용 또는 의료 보조용 반창고, 및 국소 또는 순환기계로의 약품투여의 목적으로 피부에 부착하는 파프제 등, 또한, 동물조직또는 식물, 생약 추출물을 보습성분 등으로서 함유시킨 미용을 목적으로 하는 피부손질용 시트를 등, 어깨 등의 검버섯 제거나 흡출물, 여드름, 티눈, 못류의 제거에 사용하는 경우, 탈모용 점착제가 도포된 탈모 테이프, 창상피복재, 외과용 테이프 등에 널리 적용된다.Regardless of the application, it may also be used as a medical or medical aid bandage that adheres directly onto the skin for patch tests, wound hemostasis, disinfection, protection, etc., and for the purpose of administering drugs to topical or circulatory machines. Skin care sheets containing cosmetics containing animal tissues, plants or herbal extracts as moisturizing ingredients, etc., etc. When used for removal, it is widely applied to a hair loss tape coated with a hair loss adhesive, a wound dressing, a surgical tape and the like.
즉, 본 발명은 유연성을 갖는 기재와 치료용 약제를 혼입시킨 접착(점착)제층을 갖추고, 피부 등에 부착되는 것이면, 패치라는 명칭의 사용 여하에 관계없이 널리 적용가능하다. 예컨대, 테이프의 접착제 부분에, 협심증이나 울혈성 심부전 치료약으로서의 니트로글리세린 용액을 포함하는 감압성 테이프 등에도 적용할 수 있다. 또한, 고분자 매트릭스 중에 β차단제를 함유시켜, 매트릭스 자체에는 피부 점착력은 없고, 점착 테이프에 의해 매트릭스 중의 β차단제를 피부에 밀봉투여하는 파프제 등에도 적용할 수 있다. 이들 경우에는, 테이프 그 자체가 유연성을 갖는 기재에 해당한다. 또한, 유연성을 갖는 기재에 담지된 접착제층에 국소마취약으로서의 염산리그노카인 용액을 함유시킨 경피흡수 마취제 등에도 적용된다. 경피흡수용 플라스터 시트 뿐만 아니라, 방수용 필름, 창상 피복용 통기성 시트 등, 소위 드레싱 시트 등에도 적용된다.That is, the present invention can be widely applied irrespective of the use of the name patch as long as it has an adhesive (adhesive) agent layer in which a flexible substrate and a therapeutic agent are mixed and adhered to skin or the like. For example, it can be applied to a pressure-sensitive tape containing a nitroglycerin solution as an agent for treating angina or congestive heart failure in the adhesive portion of the tape. Further, the β-blockers are contained in the polymer matrix, and the matrix itself does not have skin adhesiveness, and the present invention can also be applied to a patch or the like that seals and administers the β-blockers in the matrix to the skin by means of an adhesive tape. In these cases, the tape itself corresponds to a flexible substrate. The present invention is also applied to a transdermal absorption anesthetic agent in which a lignocaine hydrochloride solution as a local anesthetic drug is contained in an adhesive layer supported on a flexible substrate. It is applied not only to a transdermal absorption plaster sheet but also to a so-called dressing sheet and the like such as a waterproof film and a breathable sheet for wound coating.
또한, 상술한 제 1 및 제 2 실시예에서는 지지부재와 벨트부 사이에 몇개의 손가락을 삽입하여 부착하는 비교적 대형인 패치에 관해 기술하였지만, 후술하는 청구의 범위의 제 1 항으로부터 명백하듯이, 본 발명은 예컨대, 항진균제 등을 혼입시킨 감압성 접착제층이 박층상으로 형성된 치료용 접착 테이프 또는 시트를 무좀 치료의 목적으로 발가락 등에 부착하는 등, 보다 소형인 패치에도 적용되는 것은 물론이다.Further, while the above-described first and second embodiments have described a relatively large patch for inserting and attaching a few fingers between the support member and the belt portion, as apparent from claim 1 below, The present invention is, of course, applied to a smaller patch such as a pressure-sensitive adhesive layer incorporating an antifungal agent or the like attached to a toe or the like for treating athlete's foot with a therapeutic adhesive tape or sheet formed in a thin layer.
한편, 역시 상기 청구의 범위의 제 1 항으로부터 이해되는 바와 같이, 유연성을 갖는 기재를 갖춰 환부에 부착되는 것이면, 예컨대, 키틴을 이용한 열상, 외상, 채피창 등의 창상 치료용 내지 보호용 테이프를 포함할 뿐만 아니라, 기재에 약제를 전혀 포함하지 않는 단순한 가제를 부착시킨 환부 보호용 접착 테이프 또는 시트와 같은 패치에도 적용가능하다. 또한, 기재에 자석(자성체)을 부착시킨 어깨 뻐근함 등의 경감을 목적으로 하는 파프제 등에도 적용되는 것은 물론이다.On the other hand, as also understood from claim 1 of the claims, if it is attached to the affected area with a flexible substrate, for example, wounds or wound tapes for the treatment of wounds, such as lacerations, traumas, skin windows using chitin In addition, the present invention is also applicable to patches such as a wound protective adhesive tape or sheet having a simple gauze containing no medicament on the substrate. In addition, it goes without saying that it is also applied to a pape agent etc. for the purpose of alleviating shoulder stiffness which attached the magnet (magnetic substance) to the base material.
상술한 바와 같이, 본 발명은 경피흡수가능한 의약의 약효성분을 포함하는 많은 패치에 관해 적용할 수 있지만, 해열소염진통제의 예로는 인도메타신, 디클로페낙나트륨, 살리실산메틸, 살리실산모노글리콜, 아스피린, 아세트아미노펜, 이부프로펜, 슬린닥, 나프로록센, 케토프로펜, 플루페남산, 이부페낙, 펜부펜, 알클로페낙, 페닐부타존, 메페남산, 벤다작, 피록시캄, 플루르비프로펜, 펜타조신, 염산부프레노르핀, 주석산부토르파놀 등의 비스테로이드계 항염증제를 들 수 있다.As described above, the present invention can be applied to many patches containing the active ingredient of transdermally absorbable medicine, but examples of antipyretic analgesics include indomethacin, diclofenac sodium, methyl salicylate, monosalicylic acid, aspirin, acet Aminophene, ibuprofen, slyndaq, naproroxen, ketoprofen, flufenamic acid, ibufenac, fenbufen, alclofenac, phenylbutazone, mefenamic acid, bendazac, pyrocampam, flurbiprofen, Nonsteroidal anti-inflammatory agents, such as pentazocin, the buprenorphine hydrochloride, and the butanol stannate, are mentioned.
스테로이드계 항염증제의 예로는 하이드로코티손, 프레드니솔론, 플루오시놀론아세토니드, 플루드록시코티드, 메틸프레드니솔론, 초산하이드로코티손, 트리암시놀론아세토니드, 덱사메타존, 초산베타메타존, 길초산디플루코톨론, 프로피온산클로베타졸, 플루오시노니드 등을 들 수 있다.Examples of steroidal anti-inflammatory agents include hydrocortisone, prednisolone, fluorocinolone acetonide, fluoxycortide, methylprednisolone, hydrocortisone, triamcinolone acetonide, dexamethasone, beta metazone, dimethyl acetate, and propionic acid Clobetasol, fluorinide, and the like.
혈관확장제의 예로는 딜티아젬, 베라파밀, 사질산펜타에리드리톨, 디피리다몰, 질산이소소르비드, 니페디핀, 니트로글리세린 등을 들 수 있다.Examples of vasodilators include diltiazem, verapamil, pentaerythritol tetranitride, dipyridamole, isosorbate nitrate, nifedipine, nitroglycerin, and the like.
고혈압ㆍ부정맥용제로는 부프라놀롤, 프로파노롤, 아테놀롤, 핀돌롤, 황산퀴니딘, 아즈말린, 염산알프레놀롤, 주석산메토프롤롤, 나돌롤, 말레인산티몰롤, 디소피라미드 등을 들 수 있다.Examples of the hypertension / arrhythmic solvents include bupranolol, propanolol, atenolol, pindolol, quinidine sulfate, azmalin, alprenolol hydrochloride, metoprolol, nadolol, timolol maleate, and disopyramid.
혈압강하제의 예로는 염산클로니딘, 카프토푸릴, 염산프라조신, 황산펜부톨롤, 초산구아나벤즈, 염산구안파신, 염산부나조신, 말레인산에날라프릴, 염산아로티놀롤, 염산부니트롤롤 등을 들 수 있다.Examples of blood pressure lowering agents include clonidine hydrochloride, captopuryl hydrochloride, prazosin hydrochloride, fenbutolol sulfate, guanabenz acetate, guanfasin hydrochloride, buenazosin hydrochloride, enalapril hydrochloride, arotinol hydrochloride, and bunitrol hydrochloride. Can be.
진핵거담제의 예로는 염산프로카테롤, 황산테르부탈린, 브롬화수소산페노테롤, 염산툴로부테롤, 염산암브록솔, 염산피르부테롤, 염산마부테롤, 염산클렌부테롤, 염산트리메토퀴놀, 푸마르산포르모테롤 등을 들 수 있다.Examples of eukaryotic expectorants include procaterol hydrochloride, terbutaline sulfate, phenoterol hydrobromide, tulobuterol hydrochloride, ambroxol hydrochloride, pybuterol hydrochloride, mabuterol hydrochloride, clenbuterol hydrochloride, trimethoquinol hydrochloride, Fumaric acid formoterol and the like.
항종양제로는 5-플루오로우라실, 1-(2-테트라히드로푸릴)-5-플루오로우라실, 마이토마이신 C 등이 예시된다.Antitumor agents include 5-fluorouracil, 1- (2-tetrahydrofuryl) -5-fluorouracil, mitomycin C and the like.
국소마취제로는 벤조카인, 프로카인, 리그노카인, 테트라카인 등이 예시된다.Local anesthetics include benzocaine, procaine, lignocaine, tetracaine and the like.
호르몬제의 예로는 에스트로겐, 에스트라디올, 테스토스테론, 프로게스테론등의 스테로이드 호르몬류나, 인슐린 등의 펩티드 호르몬류, 프로스타글란딘 등을 들 수 있다.Examples of hormonal agents include steroid hormones such as estrogen, estradiol, testosterone and progesterone, peptide hormones such as insulin, prostaglandins and the like.
천식ㆍ비성 알레르기 치료제로는 푸마르산케토티펜, 염산아젤라스틴, 크로모글리크산나트륨 등이 예시된다.Examples of therapeutic agents for asthma and nasal allergies include fumarate ketotifen, azelastine hydrochloride and sodium chromoglycolate.
항히스타민제로는 염산사이클로헵타딘, 염산디펜히드라민, 펜벤자민, 메퀴타진 등이 예시된다.Examples of the antihistamine include cycloheptadine hydrochloride, diphenhydramine hydrochloride, phenbenzamine, mequitazine and the like.
항응혈제로로는 헤파린 등을 들 수 있다.Examples of anticoagulants include heparin.
진경제로는 스코폴라민, 클로플루페롤 등이 예시된다.Examples of antispasmodics include scopolamine and clofluferol.
뇌순환ㆍ대사개선제의 예로는 빈포세틴, 염산플루나리진, 염산니카르디핀, 푸마르산브로빈카민, 메실산디히드로에르고톡신, 주석산이펜프로딜, 염산이속수프린 등을 들 수 있다.Examples of the brain circulation / metabolism improving agent include vinpocetin, flunarizine hydrochloride, nicardipine hydrochloride, bromine fumarate, mesyric acid dihydroertoxin, iphenprodyl hydrochloride and isoxupuric acid hydrochloride.
항울ㆍ항불안제의 예로는 염산마프로틸린, 에티졸람, 디아제팜, 브로마제팜, 염산아미트립틸린, 염산미안세린 등을 들 수 있다.Examples of antidepressant and anti-anxiety agents include maprotiline hydrochloride, ethizolam, diazepam, bromazepam, amitriptyline hydrochloride, and myan serine hydrochloride.
비타민 D 제제의 예로는 알파칼시돌, 에르고칼시페롤 등을 들 수 있다.Examples of vitamin D preparations include alpha calcidol, ergocalciferol and the like.
혈당강하제의 예로는 글리벤클라미드, 글리클라지드 등을 들 수 있다.Examples of hypoglycemic agents include glybenclamide, glyclazide, and the like.
항궤양제의 예로는 말산클레보프리드, 파모티딘, 브롬화글리코피로늄 등을 들 수 있다.Examples of anti-ulcer agents include malic acid clevoprid, pamotidine, glycopyrronium bromide, and the like.
수면제의 예로는 페노바르비탈, 아모바르비탈 등을 들 수 있다.Examples of sleeping pills include phenobarbital, amobarbital, and the like.
항생물질로는 테트라사이클린, 클로람페니콜 등이 예시된다.Examples of antibiotics include tetracycline, chloramphenicol and the like.
또한, 아드레날린 작동성 기관지 확장제로서, α-[1-(메틸아미노)에틸]벤젠메탄올(에페드린), 마약 진통제로서 유용한 N-페닐-N-[1-(2-페닐에틸)-4-피페리디닐]프로판아미드, 이뇨제로서 6-클로로-3,4-디히드로-2H-1,2,4-벤조티아디아진-7-술폰아미드, 1,1-디옥사이드, 항히스타민제로서 2-디페닐메톡시-N,N-디메틸에탄아민(디펜히드라민), 에스트로겐인 에스트라-1,3,5(10)-트리엔-3,17β-디올(에스트라디올), 진경제ㆍ최면약 및 진정제로서 5-에틸-5-페닐-2,4,6(1H,3H,5H)-피리미딘트리온 등도 들 수 있다.Also, α- [1- (methylamino) ethyl] benzenemethanol (ephedrine), N-phenyl-N- [1- (2-phenylethyl) -4-piperidi, useful as an analgesic drug as an adrenergic bronchodilator Nyl] propanamide, 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide as diuretic, 1,1-dioxide, 2-diphenylme as antihistamine Methoxy-N, N-dimethylethanamine (diphenhydramine), estrogen estra-1,3,5 (10) -triene-3,17β-diol (estradiol), 5-as antispasmodic, hypnotic and sedative Ethyl-5-phenyl-2,4,6 (1H, 3H, 5H) -pyrimidinetrione and the like.
살균제로는 클로르헥시딘디글리코네이트, 아크리놀 등을 들 수 있다.Examples of the fungicides include chlorhexidine diglyconate and acrilin.
관혈관확장제로는 니트로글리세린, 이소소르비트디니트레이트, 글리콜디니트레이트, 트리에탄올아민트리니트레이트, 사질산펜타에리드리톨, 프로바틸니트레이트, 니코란딜 등이 예시된다.Examples of the vasodilator include nitroglycerin, isosorbitol dinitrate, glycol dinitrate, triethanolamine trinitrate, pentaerythritol tetrapropylate, probatylnitrate, nicorandil and the like.
정신안정제로는 플루페나진, 티올리다신, 디아제팜등이 예시된다.Examples of mental stabilizers include flufenazine, thiolidacin, diazepam, and the like.
또한, 칼슘길항제, 항퍼킨슨제, 항콜린제 등도 함유하여도 좋다. 예컨대, 적절한 함유물질의 예로서 베라파밀, 갈로파밀, 아니파밀, 피페리덴, 할로페리돌 등이 예시된다.It may also contain a calcium antagonist, an anti-Parkinson's agent, an anticholinergic agent and the like. For example, verapamil, gallopamil, anipamil, piperidene, haloperidol and the like are exemplified as suitable contents.
진해제ㆍ지사약으로서, 염산모르핀, 황산모르핀 등도 들 수 있다.Examples of antitussives and antidiarrheal agents include morphine hydrochloride and morphine sulfate.
또한, 욕창 치료약으로서, 백당, 포비돈요오드 및 글리세린을 혼합한 욕창용 약제나 피부궤양 치료를 목적으로 한 패치도 들 수 있다.Examples of the pressure ulcer medication include patches for the treatment of pressure ulcers and skin ulcers in which white sugar, povidone iodine and glycerin are mixed.
냉감성 피부자극성 약물로서, l-멘톨, d1-캄파, 티몰, d-보르네올 등을 들수 있다.Examples of cold-sensitive skin irritant drugs include l-menthol, d1-campa, thymol, d-borneol and the like.
온감성 피부자극성 약물로서, 고추 추출물, 노닐산바닐릴아미드, 캅사이신, 생강 근경 추출물, 칸타리스 팅크제, 칸타리딘 등을 들 수 있다.As a sensitive skin irritant drug, there are pepper extract, nonyl acid vanylylamide, capsaicin, ginger root extract, cantharis tincture, cantharidin and the like.
심상성 백반이나 건선 등의 피부질환에 대하여 소랄렌 또는 그 유도체 등과 자외선을 병용하는 치료법에 있어서, 피부에 유해한 파장영역의 자외선을 흡수하여, 치료에 유용한 파장영역의 자외선 만을 투과시킬 수 있는 살리실산계 화합물과 2,2'-메틸렌-비스(4-에틸-6-tert-부틸페놀)을 배합한 조성물로 이루어진 유해 자외선 흡수성 점착 시트도 들 수 있다.Salicylic acid system that absorbs ultraviolet rays in wavelength range harmful to skin and transmits only ultraviolet rays in wavelength range useful for treatment in skin treatment such as vitiligo and psoriasis with sorlene or derivatives thereof and ultraviolet rays The harmful ultraviolet absorbent adhesive sheet which consists of a compound which mix | blended the compound and 2,2'-methylene-bis (4-ethyl-6-tert- butylphenol) is also mentioned.
또한, 히알루론산, 아미노산, 단백질, 호르몬류, 태반추출물질과 같은 천연물질, 계면활성물질, 피부미백작용물질, 비타민류 등의 미용활성물질을 함유시킨 미용목적의 팩제라도 좋다.It may also be a cosmetic pack containing cosmetically active substances such as natural substances such as hyaluronic acid, amino acids, proteins, hormones, placenta extracts, surfactants, skin whitening agents and vitamins.
탈모 테이프나 탈모제를 함유시킨 파프제라도 좋다.It may be a pap agent containing a hair loss tape or a hair loss agent.
복부팽만ㆍ변통불량ㆍ발열 치료를 목적으로 한 패치로서 된장을 포함한 것(된장 시트)라도 좋다.A patch for treating abdominal bloating, dysmenorrhea and fever may be included (miso sheet).
또한, 출혈 치료를 목적으로 한 창상면 보호가용성 지혈재로서, 옥시셀룰로스, 산화콜라겐, 셀룰로스나트륨, 알긴산칼슘 등을 포함시킨 것이라도 좋다.The wound surface-protective hemostatic agent for the purpose of bleeding treatment may be one containing oxycellulose, collagen oxide, sodium cellulose, calcium alginate and the like.
본 발명의 지지구는 상기와 같은 구성을 갖기 때문에, 종래의 부드러운 기재로 이루어진 패치이더라도, 부착시에 일시적으로 기재에 강성을 갖게 할 수 있다. 따라서, 패치로부터 보호용 필름 등을 벗길 때도, 또한 보호용 필름 등을 벗긴 후 패치를 원하는 환부에 접착시킬 때에도, 점착면끼리 달라 붙는 것을 유효하게 방지할 수 있다.Since the support tool of this invention has the above structures, even if it is a patch which consists of a conventional soft base material, it can make a base material rigid temporarily at the time of attachment. Therefore, even when peeling off a protective film etc. from a patch, and also when sticking a patch to a desired lesion after peeling off a protective film etc., sticking of adhesive surfaces can be effectively prevented.
또한, 벨트부를 예컨대, 지지부재의 전체 폭에 걸쳐 손가락을 삽입할 수 있는 통형상 또는 자루 형상으로 구성함으로써, 패치를 원하는 환부에 접착시킬 때에는, 지지부재와 벨트부 사이에 몇개의 손가락을 나란히 한 상태로 삽입할 수 있으므로, 패치를 스무스하게 접착시킬 수 있음과 동시에, 패치를 접착시킨 후에 지지구를 이탈시킬 때에도 이를 스무스하게 할 수 있다.In addition, by forming the belt portion into, for example, a tubular shape or a bag shape in which a finger can be inserted over the entire width of the support member, when attaching the patch to the desired affected part, several fingers are placed side by side between the support member and the belt portion. Since the patch can be inserted in a state, the patch can be smoothly adhered, and at the same time, it can be smoothed even when the support is released after the patch is adhered.
이상으로부터, 부드러운 기재를 갖춘 패치이더라도, 점착면끼리 달라 붙는 것을 방지할 수 있고, 어깨, 등, 허리 등의 환부에도 접착하기 쉽게 하는 패치용 지지구를 제공할 수 있으며, 광범위한 용도의 패치에 응용할 수 있기 때문에, 그 산업적 가치는 크다.As described above, even a patch having a soft base material can provide a support for a patch that can prevent the adhesive surfaces from sticking to each other and easily adhere to the affected areas such as the shoulder, back, and waist, and can be applied to a patch of a wide range of applications. As can be, its industrial value is great.
또한, 상기 지지구와 동일한 구성을 기재의 점착면과 반대측의 면에 갖춘 패치에 있어서는, 지지부재의 존재에 의해 기재에 강성을 갖게 할 수 있으므로, 보호용 필름 등을 벗길 때에도, 또한 보호용 필름 등을 벗겨 원하는 환부에 접착시킬 때에도, 점착면끼리 달라 붙는 일이 없다. 상기 지지구에 대한 것과 동일하게, 벨트부를 예컨대, 지지부재의 전체 폭에 걸쳐 손가락을 삽입할 수 있는 통형상 또는 자루형상으로 구성함으로써, 지지부재와 벨트부 사이에 몇개의 손가락을 나란히 한 상태로 삽입할 수 있기 때문에, 패치의 부착을 스무스하게 할 수 있음과 동시에, 지지부재를 기재로부터 이탈시킬 때에도 스무스하게 할 수 있다.In addition, in the patch provided with the same structure as the said support on the surface opposite to the adhesive surface of a base material, since a base material can give rigidity to a base material, when a protective film etc. are peeled off, a protective film etc. can also be peeled off. Even when adhering to a desired affected part, the adhesive faces do not stick together. In the same manner as that for the support, the belt portion is formed in a tubular shape or a bag shape for inserting a finger over the entire width of the support member, for example, so that a few fingers are placed side by side between the support member and the belt portion. Since it can be inserted, the patch can be smoothly attached and smoothly when the support member is separated from the substrate.
이상과 같이, 부드러운 기재를 갖춘 패치로서의 이점을 살리면서, 점착면끼리 달라 붙는 일이 없고, 어깨, 등, 허리 등의 환부에도 환자가 스스로 부착하기 쉬운 패치를 제공할 수 있기 때문에, 아이, 신체가 부자유한 사람, 시력이 약해진 노인 등이어도 스스로 환부에 부착하기 쉬우므로, 그 의료적 가치는 크다.As mentioned above, while making use of the advantage as the patch with the soft base material, the adhesive surface does not stick together and can provide the patch which a patient is easy to attach to the affected parts such as a shoulder, a back, a waist, a child, a body Even those who are inconvenient and those who have weak eyesight are more likely to attach themselves to affected areas, so their medical value is great.
Claims (9)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP23171497 | 1997-08-13 | ||
| JP97-231714 | 1997-08-13 | ||
| PCT/JP1998/003614 WO1999008664A1 (en) | 1997-08-13 | 1998-08-13 | Support for patches and patches provided with the support |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20010022758A true KR20010022758A (en) | 2001-03-26 |
Family
ID=16927872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020007001358A KR20010022758A (en) | 1997-08-13 | 1998-08-13 | Support for patches and patches provided with the support |
Country Status (3)
| Country | Link |
|---|---|
| KR (1) | KR20010022758A (en) |
| AU (1) | AU8648798A (en) |
| WO (1) | WO1999008664A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010083439A (en) * | 2000-02-14 | 2001-09-01 | 원인호 | Activated magnet paste and its preparation method |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1164361A1 (en) | 2000-06-14 | 2001-12-19 | Abb Research Ltd. | Gasmeter |
| EP3514244B1 (en) | 2009-04-03 | 2021-07-07 | Sequenom, Inc. | Nucleic acid preparation methods |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3279561D1 (en) * | 1982-09-28 | 1989-04-27 | Baxter Int | System and method for bandaging a patient |
| JPS6277314A (en) * | 1985-09-30 | 1987-04-09 | Nitto Electric Ind Co Ltd | Medicinal pharmaceutical |
| GB8721659D0 (en) * | 1987-09-15 | 1987-10-21 | Smith & Nephew Ass | Adhesive coated dressings & applicators |
-
1998
- 1998-08-13 AU AU86487/98A patent/AU8648798A/en not_active Abandoned
- 1998-08-13 WO PCT/JP1998/003614 patent/WO1999008664A1/en not_active Application Discontinuation
- 1998-08-13 KR KR1020007001358A patent/KR20010022758A/en not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010083439A (en) * | 2000-02-14 | 2001-09-01 | 원인호 | Activated magnet paste and its preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999008664A1 (en) | 1999-02-25 |
| AU8648798A (en) | 1999-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7921999B1 (en) | Peelable pouch for transdermal patch and method for packaging | |
| US5662925A (en) | Transdermal delivery system with adhesive overlay and peel seal disc | |
| US9358373B2 (en) | Transdermal patch incorporating active agent migration barrier layer | |
| JP3023989B2 (en) | Topical dressing, method of manufacturing topical dressing and use of topical dressing | |
| ES2651020T3 (en) | A bandage product | |
| US4928680A (en) | Adhesive coated dressing and applicators therefor | |
| AU2006323069B2 (en) | Two-sided non-stick release film | |
| US20100241089A1 (en) | Skin patch laminate body | |
| KR20050044656A (en) | Transdermal therapeutic system provided with improved long-term carrying comfort | |
| JP3002772B2 (en) | Patch and its manufacturing method | |
| KR20010022758A (en) | Support for patches and patches provided with the support | |
| JP4704829B2 (en) | Patch and patch package | |
| US20050118245A1 (en) | Assembled unit consisting of individually separable, transdermal, therapeutic systems | |
| JPS63284124A (en) | Poultice | |
| KR0121470Y1 (en) | bandage | |
| JP3460092B2 (en) | Method for producing ointment-based patch | |
| JP3042905U (en) | Patch | |
| BR112021009956A2 (en) | transdermal therapeutic system, its use and its production process, kit comprising at least one transdermal therapeutic system | |
| JP2000256185A (en) | Paste for athlete's foot | |
| JPH08291055A (en) | Shape memory plaster | |
| JPH11158062A (en) | Cataplasm for interdigital dermatophytosis | |
| JP2007039369A (en) | External preparation containing powder germanium | |
| JP2000229849A (en) | Tape for glass pad for easing pollinoisis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WITN | Withdrawal due to no request for examination |